Cullinan Therapeutics, Inc. (CGEM) shareholders
Close on Nov 17, 2026Market cap $596.89MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Weston Nichols Joint filing with Lynx1 Capital Management LP (14.50%) | 8,549,084 | 14.50% | 13G (passive) amendment | Oct 8, 2025 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 6,491,123 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 6,161,469 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 5,918,481 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Lynx1 Capital Management LP Joint filing with Weston Nichols (9.80%) | 5,766,090 | 9.80% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 4,338,725 | 7.50% | 13G (passive) | Sep 30, 2024 |
| T. Rowe Price Associates, Inc. | 3,825,950 | 6.20% | 13G (passive) | Jun 30, 2026 |
| Kynam Capital Management GP, LLC Joint filing with Kynam Capital Management, LP (5.27%), Yue Tang (5.27%) | 3,114,132 | 5.27% | 13G (passive) | Dec 31, 2025 |
| Morana Jovan-Embiricos | 2,177,461 | 5.09% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CGEM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mpm Bioimpact LLC | 9,731,341 | 15.12% | $177.21M | +2,083,073 | 10.81% |
| Lynx1 Capital Management LP | 8,963,500 | 13.93% | $163.23M | – | 18.86% |
| Bvf Inc/Il | 5,750,683 | 8.94% | $104.72M | – | 2.68% |
| BlackRock, Inc. | 5,232,766 | 8.13% | $95.29M | +782,800 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,825,950 | 5.95% | $69.67M | +1,796,231 | 0.01% |
| State Street Corp | 3,668,627 | 5.70% | $66.81M | +1,124,512 | 0.00% |
| Kynam Capital Management, LP | 3,114,132 | 4.84% | $56.71M | – | 3.13% |
| Vanguard Capital Management LLC | 2,614,066 | 4.06% | $47.60M | +131,032 | 0.00% |
| Rtw Investments, LP | 2,364,347 | 3.67% | $43.05M | +658,387 | 0.37% |
| Siren, L.L.C. | 1,893,410 | 2.94% | $34.48M | +700,000 | 0.70% |
| Geode Capital Management, LLC | 1,547,309 | 2.40% | $28.18M | +179,041 | 0.00% |
| Blue Owl Capital Holdings LP | 1,539,764 | 2.39% | $28.04M | −370,000 | 4.22% |
| VR Adviser, LLC | 1,379,965 | 2.14% | $25.13M | – | 0.76% |
| Boothbay Fund Management, LLC | 1,082,611 | 1.68% | $19.71M | −30,192 | 0.26% |
| Dimensional Fund Advisors LP | 1,046,694 | 1.63% | $19.06M | +140,666 | 0.00% |
| Goldman Sachs Group Inc | 1,001,598 | 1.56% | $18.24M | +546,149 | 0.00% |
| Affinity Asset Advisors, LLC | 875,760 | 1.36% | $15.95M | +94,500 | 0.72% |
| Vanguard Portfolio Management LLC | 738,741 | 1.15% | $13.45M | +186,188 | 0.00% |
| Boone Capital Management LLC | 704,442 | 1.09% | $12.83M | New | 3.00% |
| Elmind Capital, LP | 690,000 | 1.07% | $12.56M | +160,000 | 3.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 184 | 72M | 100.0% | 32 / 84 | 47 / 20 | 12M | 6M |
| Q1 2026 | 174 | 66M | 100.0% | 40 / 61 | 42 / 17 | 11M | 5M |
| Q4 2025 | 153 | 63M | 98.2% | 29 / 66 | 41 / 18 | 13M | 11M |
| Q3 2025 | 145 | 61M | 95.0% | 28 / 56 | 37 / 26 | 5M | 6M |
| Q2 2025 | 143 | 63M | 97.3% | 20 / 51 | 45 / 24 | 3M | 5M |
| Q1 2025 | 148 | 65M | 100.0% | 27 / 45 | 50 / 23 | 7M | 7M |
| Q4 2024 | 146 | 66M | 100.0% | 30 / 54 | 36 / 20 | 8M | 8M |
| Q3 2024 | 137 | 65M | 100.0% | 20 / 66 | 28 / 17 | 13M | 7M |
| Q2 2024 | 135 | 63M | 97.8% | 39 / 60 | 26 / 16 | 28M | 7M |
| Q1 2024 | 113 | 42M | 64.8% | 19 / 41 | 37 / 18 | 8M | 4M |
| Q4 2023 | 113 | 38M | 58.8% | 23 / 45 | 25 / 14 | 8M | 5M |
| Q3 2023 | 106 | 38M | 59.5% | 13 / 35 | 31 / 13 | 3M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
176 funds held CGEM in Q2 2026, 61% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CGEM | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,377,645 | 3.69% | $43.30M | 0.40% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,929,766 | 3.00% | $35.14M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,577,982 | 2.45% | $28.74M | 0.03% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,019,356 | 1.58% | $18.56M | 0.13% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 660,987 | 1.03% | $10.91M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 621,218 | 0.97% | $11.31M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 583,803 | 0.91% | $10.63M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 562,565 | 0.87% | $10.24M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 559,800 | 0.87% | $10.19M | 0.10% | Jun 30, 2026 |
| iShares Biotechnology ETF | 318,933 | 0.50% | $5.81M | 0.06% | Jun 30, 2026 |
| Vanguard Explorer Fund | 303,486 | 0.47% | $5.01M | 0.02% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 301,774 | 0.47% | $4.98M | 0.12% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 277,141 | 0.43% | $4.56M | 0.03% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 266,914 | 0.41% | $4.39M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 246,130 | 0.38% | $4.05M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nadim Ahmed | President and CEO, Director | 390,803 | 0.61% | Feb 25, 2026 |
| Jennifer Michaelson | Chief Scientific Officer | 158,649 | 0.25% | Nov 6, 2026 |
| Jacquelyn L. Sumer | Chief Legal Officer | 130,559 | 0.20% | Jul 2, 2026 |
| Mary Kay Fenton | Chief Financial Officer | 127,921 | 0.20% | Jul 2, 2026 |
| Jeffrey Alan Jones | Chief Medical Officer | 159,968 | 0.25% | Feb 25, 2026 |
| Corrine Savill | Chief Business Officer | 240,990 | 0.37% | Feb 19, 2026 |
| Andrew R. Allen | Director | – | – | Jun 18, 2026 |
| Mary Thistle | Director | – | – | Jun 18, 2026 |
| Stephen W. Webster | Director | – | – | Jun 18, 2026 |
| David D. Meek | Director | – | – | Jun 18, 2026 |
| Anthony Rosenberg | Director | 45,002 | 0.07% | Jun 18, 2026 |
| Mittie Doyle | Director | – | – | Jun 18, 2026 |
| Anne-Marie Martin | Director | – | – | Jun 16, 2025 |
| David P. Ryan | Director | – | – | Jun 16, 2025 |
| Capital Management LP Lynx1 | 10% owner | 8,797,833 | 13.67% | Oct 30, 2025 |
| Weston Nichols | 10% owner | 8,963,500 | 13.93% | Oct 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Michaelson Chief Scientific Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −4,000 | $12.36 | $49.44K | 158,649 |
| Jennifer Michaelson Chief Scientific Officer | Nov 5, 2026 | Option exercise | +3,805 | $4.30 | $16.36K | 162,649 |
| Jennifer Michaelson Chief Scientific Officer | Sep 8, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 166,844 |
| Jennifer Michaelson Chief Scientific Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −8,000 | $21.57 | $172.56K | 158,844 |
| Jennifer Michaelson Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −30,000 | $20.26 | $607.80K | 162,844 |
| Jennifer Michaelson Chief Scientific Officer | Aug 13, 2026 | Option exercise | +30,000 | $4.30 | $129.00K | 192,844 |
| Jennifer Michaelson Chief Scientific Officer | Jul 6, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 170,844 |
| Jennifer Michaelson Chief Scientific Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −8,000 | $17.82 | $142.56K | 162,844 |
| Jacquelyn L. Sumer Chief Legal Officer | Jun 30, 2026 | Award | +2,470 | $8.60 | $21.24K | 130,559 |
| Mary Kay Fenton Chief Financial Officer | Jun 30, 2026 | Award | +1,541 | $8.60 | $13.25K | 127,921 |
| Jennifer Michaelson Chief Scientific Officer | May 5, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 174,844 |
| Jennifer Michaelson Chief Scientific Officer | May 5, 2026 | Sale(10b5-1 plan) | −7,800 | $14.60 | $113.88K | 167,044 |
| Jennifer Michaelson Chief Scientific Officer | May 5, 2026 | Sale(10b5-1 plan) | −200 | $15.58 | $3.12K | 166,844 |
| Jennifer Michaelson Chief Scientific Officer | Mar 5, 2026 | Sale(10b5-1 plan) | −8,000 | $15.68 | $125.44K | 170,844 |
| Jennifer Michaelson Chief Scientific Officer | Mar 5, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 178,844 |
| Jennifer Michaelson Chief Scientific Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −1,780 | $14.14 | $25.17K | 174,844 |
| Jennifer Michaelson Chief Scientific Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −3,601 | $14.47 | $52.11K | 176,624 |
| Nadim Ahmed President and CEO, Director | Feb 24, 2026 | Sale | −13,515 | $14.47 | $195.56K | 390,803 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 24, 2026 | Sale | −3,601 | $14.47 | $52.11K | 128,089 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 24, 2026 | Sale | −4,582 | $14.47 | $66.30K | 159,968 |
| Jennifer Michaelson Chief Scientific Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −1,752 | $13.99 | $24.51K | 180,225 |
| Nadim Ahmed President and CEO, Director | Feb 20, 2026 | Sale | −16,381 | $13.62 | $223.11K | 404,318 |
| Jennifer Michaelson Chief Scientific Officer | Feb 20, 2026 | Sale(10b5-1 plan) | −3,742 | $13.62 | $50.97K | 181,977 |
| Jennifer Michaelson Chief Scientific Officer | Feb 20, 2026 | Option exercise | +8,000 | $4.30 | $34.40K | 189,977 |
| Jennifer Michaelson Chief Scientific Officer | Feb 20, 2026 | Sale(10b5-1 plan) | −8,000 | $14.30 | $114.40K | 181,977 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 20, 2026 | Sale | −3,742 | $13.62 | $50.97K | 131,690 |
| Mary Kay Fenton Chief Financial Officer | Feb 20, 2026 | Sale | −4,398 | $13.62 | $59.90K | 126,380 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 20, 2026 | Sale | −4,982 | $13.62 | $67.85K | 164,550 |
| Mary Kay Fenton Chief Financial Officer | Feb 18, 2026 | Award | +68,750 | – | – | 130,778 |
| Jennifer Michaelson Chief Scientific Officer | Feb 18, 2026 | Award | +57,500 | – | – | 185,719 |
| Jennifer Michaelson Chief Scientific Officer | Feb 12, 2026 | Sale | −416 | $12.03 | $5.00K | 128,219 |
| Jennifer Michaelson Chief Scientific Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −4,000 | $12.30 | $49.20K | 128,635 |
| Mary Kay Fenton Chief Financial Officer | Dec 31, 2025 | Award | +27 | $6.49 | $175 | 62,028 |
| Nadim Ahmed President and CEO, Director | Dec 23, 2025 | Sale | −9,922 | $10.01 | $99.32K | 420,699 |
| Jennifer Michaelson Chief Scientific Officer | Dec 19, 2025 | Sale(10b5-1 plan) | −1,345 | $10.01 | $13.46K | 132,635 |
| Jacquelyn L. Sumer Chief Legal Officer | Dec 18, 2025 | Sale | −3,480 | $9.67 | $33.65K | 135,432 |
| Jeffrey Alan Jones Chief Medical Officer | Dec 18, 2025 | Sale | −4,632 | $9.67 | $44.79K | 169,532 |
| Jennifer Michaelson Chief Scientific Officer | Dec 18, 2025 | Sale | −2,898 | $9.67 | $28.02K | 133,980 |
| Jennifer Michaelson Chief Scientific Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −995 | $11.90 | $11.84K | 136,878 |
| Jennifer Michaelson Chief Scientific Officer | Dec 12, 2025 | Sale(10b5-1 plan) | −2,148 | $12.38 | $26.59K | 137,873 |
| Jennifer Michaelson Chief Scientific Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −4,000 | $12.30 | $49.20K | 138,004 |
| Weston Nichols 10% owner | Oct 28, 2025 | Buy | +165,667 | $8.40 | $1.39M | 8,963,500 |
| Capital Management LP Lynx1 10% owner | Oct 17, 2025 | Buy | +32,217 | $7.84 | $252.58K | 8,797,833 |
| Capital Management LP Lynx1 10% owner | Oct 16, 2025 | Buy | +150,000 | $8.86 | $1.33M | 8,765,616 |
| Capital Management LP Lynx1 10% owner | Oct 15, 2025 | Buy | +51,500 | $7.94 | $408.91K | 8,615,616 |
| Capital Management LP Lynx1 10% owner | Oct 14, 2025 | Buy | +15,032 | $7.59 | $114.09K | 8,564,116 |
| Capital Management LP Lynx1 10% owner | Oct 10, 2025 | Buy | +277,298 | $7.36 | $2.04M | 8,549,084 |
| Capital Management LP Lynx1 10% owner | Oct 9, 2025 | Buy | +626,043 | $6.70 | $4.19M | 8,271,786 |
| Capital Management LP Lynx1 10% owner | Oct 8, 2025 | Buy | +556,300 | $6.46 | $3.59M | 7,645,743 |
| Nadim Ahmed President and CEO, Director | Feb 25, 2025 | Sale | −12,529 | $8.53 | $106.87K | 430,621 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 25, 2025 | Sale | −4,895 | $8.53 | $41.75K | 174,164 |
| Jennifer Michaelson Chief Scientific Officer | Feb 25, 2025 | Sale | −3,756 | $8.53 | $32.04K | 142,004 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 25, 2025 | Sale | −3,756 | $8.53 | $32.04K | 136,895 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 19, 2025 | Award | +65,000 | – | – | 179,059 |
| Nadim Ahmed President and CEO, Director | Feb 19, 2025 | Award | +180,000 | – | – | 443,150 |
| Corrine Savill Chief Business Officer | Feb 19, 2025 | Award | +37,500 | – | – | 240,990 |
| Mary Kay Fenton Chief Financial Officer | Feb 19, 2025 | Award | +60,000 | – | – | 60,000 |
| Jennifer Michaelson Chief Scientific Officer | Feb 19, 2025 | Award | +50,000 | – | – | 145,760 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 19, 2025 | Award | +50,000 | – | – | 140,651 |
| Jennifer Michaelson Chief Scientific Officer | Jan 6, 2025 | Sale(10b5-1 plan) | −4,000 | $12.51 | $50.04K | 95,760 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cullinan Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,411 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jennifer Michaelson Officer | Nov 5, 2026 | 4,000 | $49.96K | Nov 5, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | Sep 8, 2026 | 8,000 | $176.72K | Sep 8, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | Aug 13, 2026 | 30,000 | $588.00K | Aug 13, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | Jul 6, 2026 | 8,000 | $141.04K | Jul 6, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | May 5, 2026 | 8,000 | $122.72K | May 5, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | Mar 5, 2026 | 8,000 | $130.40K | Mar 5, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | Feb 25, 2026 | 1,780 | $25.40K | Feb 25, 2026 | Restricted Stock Units |
| Jennifer Michaelson Officer | Feb 23, 2026 | 1,752 | $23.91K | Feb 23, 2026 | Restricted Stock Units |
| Jennifer Michaelson Officer | Feb 20, 2026 | 8,000 | $111.04K | Feb 20, 2026 | Exercise of Stock Options |
| Jennifer Michaelson Officer | Jan 22, 2026 | 4,000 | $46.40K | Jan 22, 2026 | Restricted Stock Units |
| Jennifer Michaelson Officer | Dec 19, 2025 | 1,345 | $13.42K | Dec 19, 2025 | Restricted Stock Units |
| Jennifer Michaelson Officer | Dec 15, 2025 | 995 | $11.86K | Dec 15, 2025 | Restricted Stock Units |
| Jennifer Michaelson Officer | Nov 24, 2025 | 4,000 | $37.88K | Nov 24, 2025 | Restricted Stock Units |
| Jennifer Michaelson Officer | Jan 6, 2025 | 8,000 | $101.44K | Jan 6, 2025 | Restricted Stock Units |
| Jennifer Michaelson & Marc D Michaelson Officer | Sep 5, 2024 | 16,000 | $298.88K | Sep 5, 2024 | Restricted Stock Awards |
See a number that looks wrong?